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From available literature, there is strong evidence that the growth of tumours is to a great
extent influenced by the cellular response of the immune system in addition to the therapy
administered. While chemotherapy treatment is very effective in killing cancer cells, the
levels of toxicity associated with it affects other body cells negatively, the worst of which
are cells with higher rate of multiplication and regeneration. A lot of research, with im-
pressive results has been carried out in cancer for the past over four decades, yet there
is still not a universally accepted effective mathematical model that provides a way of
optimizing chemotherapy efficacy and toxicity.
The mathematical model developed in this research has provided a theoretical understand-
ing of the interactions among cancer cells and body cells for cancer patients as well as
laying the stage for future research work. Based on the findings from reviewed biolog-
ical literature, a mathematical model comprising of six ODEs describing the growth of
tumour cells while incorporating the immune system response and chemotherapy treat-
ment was formulated and analyzed both analytically and numerically. Three scenarios are
presented namely: no tumour with no treatment, tumour with no treatment and tumour
with treatment. In the first case (no tumour and no treatment), the system was found to
be stable. The tumour with no treatment equilibrium was on the other hand was found
be unstable implying that the immune system can not eliminate cancer cells on their own.
Lastly, the case of tumour with treatment was found to be stable hence longer survival
times for the patients receiving chemotherapy treatment. When however, the concentra-
tion of chemotherapy was increased, the system goes back to instability due to the decline
of the number of NK and CD8+ T-cells as a result of chemotherapeutic toxicity.
According to the results of the formulated mathematical model, treatment regimens con-
sisting of right concentrations of chemotherapy is effective in eliminating the tumour cell
population. Further research should therefore focus on developing models that quantify
the optimal drug concentration for maximum efficacy on tumour cells with minimal toxi-
city to immune cells.
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Cancer is an uncontrollable multiplication of cells (Figure 1.1) caused by multiple changes
in gene expression leading to the dysregulated balance of cell proliferation and cell death
and ultimately evolving into a population of cells that can invade tissue and metastasize
to distant sites (Ruddon, 2007). These physiological changes in the genetic behaviour
of cells lead to a progressive loss and the consequent malfunction of body cells. In the
absence of effective treatment, death by cancer is caused by the relentless increase in the
population of these abnormally dividing cells, otherwise referred to as cancerous cells
(Ruddon, 2007).
Figure 1.1: Comparison between cell division in normal body cells and cancerous cells
(AACR, 2016)
The World Health Organization, ranks cancer as the second leading cause of death in the
world accounting for 8.8 million (13%) deaths in the year 2015. This number of new cases
is expected to rise by approximately 70% within the next two decades. Essentially, what
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this means is that there will be an estimated number of 24 million new cases of cancer
annually in the year 2032 (WHO, 2016). In Kenya, cancer is ranked as the third leading
cause of death accounting for 7 per cent of the total annual mortality behind infectious
and cardiovascular diseases (MOH-Kenya, 2011). Although data about population is not
available in the country, the annual incidence of cancer is about 28,000 cases with an
annual mortality of over 22,000 (MOH-Kenya, 2011).
It is clear from this statistics that cancer posses a great burden to the population, and the
fight against it has become of create concern for public health officials not only nationally
but also globally. A greater understanding of the dynamics of cancer indeed has a great
potential of providing solutions to the cancer problem. There can not be a better way to
clearly understand cancer dynamics other than the application of mathematical models.
It is with this understanding that scientists have, for the past over four decades, been
developing mathematical models that mainly study and explain the dynamics of tumour
growth. Evidently, a breakthrough in this determination has a great potential to save the
many lives that are currently at risk.
1.2 Biological background of cancer
1.2.1 Cancer
As already defined, cancer is an abnormal growth of cells caused by multiple changes
in gene expression leading to the dysregulated balance of cell proliferation, death and
ultimately evolving into a population of cells that can invade tissue and metastasize to
distant sites (Ruddon, 2007). Cancer occurs when there are genetic mutations which can
be as a result of many causes, among them, physical carcinogens (ultraviolet and ionizing
radiation), chemical carcinogens (asbestos, components of tobacco smoke, aflatoxin and
arsenic) and biological carcinogens (viral, bacterial and parasite infections) (WHO, 2016).
Tumour formation is the result of passing of these mutations through the generations of the
cell’s progeny (Fechheimer and Karp, 2000). A population of cells is said to be cancerous
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if the mutations result in the uncontrolled proliferation and intrusion into nearby tissues,
thus interfering with normal functioning of normal body cells. In the absence of effective
treatment, these interference bears negative effects to the ultimate survival of the organism,
and in some cases, leads to death (Hanahan and Weinberg, 2000).
1.2.2 The biology of tumours
Under normal circumstances, cells grow, divide in a manner that is orderly and the for-
mation of tissues and organism is done to achieve a specified function in the body. In
some instances however, some cells, after developing a random genetic mutation divide
uncontrollably forming a mass referred to as tumour or neoplasm (Melicow, 1982). These
tumours give the cells all or any combination of the following capabilities.
i.) Apoptosis avoidance: Cells avoid the trigger that causes them to die naturally when-
ever they begin to behave abnormally.
ii.) Self-sufficient growth signaling: Increased production of pro-growth factors or height-
ened sensitivity to them.
iii.) Anti-growth signal insensitivity: Avoidance of differentiation or the quiescent state.
iv.) Angiogenesis promotion: upregulation of proangiogenic factors and insensitivity to
angiogiogenic factors, leading to tumour vasculature.
v.) Senescence prevention: Unlimited replicative potential.
vi.) Invasion: Ability to move to surrounding tissues.
vii.) Metastasis: Ability to travel and colonize distant regions of the organism.
1.2.3 Benign and malignant tumours
There are two groups of tumours namely benign and malignant. Benign tumours are non-
invasive and non-metastasis and are generally non-life threatening. They can however
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sometimes be fatal in two ways namely: if they develop in some parts of the body e.g.
the brain and if they acquire some additional mutations. On the other hand, malignant
tumours are characterized by their great ability to grow and divide uncontrollably, invade
nearby tissues what is referred to as invasion and to spread to other parts of the body by a
process called metastasis. Malignant tumours are potentially fatal.
Metastasis, the spreading of tumour cells to other parts of the body is achieved through the
bloodstream and the lymphatic system in which case, the cells are carried and lodged some
distance away from the initial point as shown in Figure 1.2. where they begin to invade
and colonize the surrounding tissue. While some tumours grow, invade and metastasize
quickly leading to death in a short period of time, there are others that stay in the body for
several years without showing any symptoms (Hanahan and Weinberg, 2000).
Figure 1.2: Tumour angiogenesis and metastasis in cancerous cells (Divoli et al., 2011)
1.2.4 Tumour angiogenesis
Just like any other cells of a living organism, the growth of tumours is very much depen-
dent on the supply of oxygen and nutrients. In the initial stages, this supply of oxygen
and nutrients is not a big problem since they (oxygen and nutrients) diffuse from the sur-
rounding cells into the tumour quite easily. However, as the tumour continues to increase
in volume, usually from 2-3millimeters in diameter, diffusion becomes limited. As an
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adaptation, tumour cells begin to release hypoxia-induced factors (HIFs), which trigger
the release of proangiogenic factors in nearby cells among them being the vascular en-
dothelial growth factor (VEGF). This causes blood vessels to sprout from nearby existing
vasculature in a manner that is unregulated with the aim of supplying oxygen and nutrients
to the growing tumour (Phipps, 2009). This is represented by the red branches as appears
in Figure 1.2.
1.3 Tumour and immune cells interaction
The immune system is a collection of mechanisms and processes inside the body of an or-
ganism with the purpose of providing protection to the organism against foreign material.
The immune system achieves its functions by recognizing and eliminating foreign matter
that include viral particles, parasites, and, in this particular case tumour cells (Chang et al.,
2003). The two main types of immune cells that respond to the presence of tumour cells
in the body are non-specific immune cells (innate immune system) and specific immune
cells (adaptive immune system). The non-specific immune cells e.g. natural killer (NK)
cells travel throughout the body and attack any foreign matter they come across. Specific
immune cells on the other hand only attack foreign material after being primed by some
mechanisms Melicow (1982). CD8+ T-cells is an example of cells that are categorized
under the adaptive immune system.
1.3.1 Natural Killer (NK) cells
These are a type of non-specific white blood cells that forms the body’s first line of defence
against infection and diseases. They are always present in the body of a healthy organism
traveling through the bloodstream and the lymphatic system to the extracellular fluid and
destroy any foreign matter that they come across (Cabrera et al., 1996). There are two
ways that NK cells are adapted to recognizing tumour cells. In the first case, they are
attracted to tumour cells by certain tumour antigens and once there, they kill the tumour
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cells. In the second case, the NK cells destroy abnormal cancer cells before they replicate
and grow (van der Merwe and Davis, 2002). Their recruitment of has been defined as a
function of both tumour cell population T (t) and the available NK cell population N(t).
Algebraically, their recruitment takes the form presented in Equation (1.1).






Equation (1.1) is the Michaelis-Menten term which is commonly used in tumour growth
models to describe cell-cell interactions (de Pillis et al., 2005). The term, in addition to
others, was included in the model of equations developed as part of this research to account
for the increase in the NK cells as a result of their interaction with tumour cells.
1.3.2 CD8+ T-cells
Unlike the NK cells, CD8+ T-cells first need to be activated before they can move to and
attack the tumour cells. The activation of the CD8+ T-cells is dependent on the following:
• Population of tumour cells that have been killed by other CD8+ T-cells.
• Debris from tumour cells killed by NK cells.
• Presense of tumour cells in the blood stream which causes the other circulating
lymphocytes to signal their activation.
The above were considered as part of the factors that describe the dynamics of the CD8+
T-cells populations under Section 3.2.
Activation of CD8+ T-cells takes place in the lymph nodes where they are presented with
antigens specific to the tumour cells. Two types of tumour antigens have been identified on
tumour cells: tumour-specific transplantation antigens (TSTAs) that are unique to tumour
cells and do not occur in normal body cells. The second type are the tumour-associated
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transplantation antigens (TATAs) which are not unique to tumour cells and are expressed
on normal body cells during fetal development (Jackson, 2003).
Once primed a majority of these cells, the cytotoxic T-cells, multiply, and leave the lymph
node to find the source of the tumour antigens presented to them. Though the process
by which the movement of these cells to the sources is not well understand, a number of
researchers agree that one possible mechanism is chemostatic gradient, a process by which
the CD8+ T-cells travel up to get to the tumour cells by following chemical gradients.
Once at the target site, the CD8+ T-cells kill tumour cells either by inserting signals that
causes apoptosis in the tumour cells or binding to the Fas ligand (FasL or CD95L) on
the outside of the tumour cells then using it to induce apoptosis (Delves and Roitt, 2000).
Fas ligand is a type-II trans-membrane protein that belongs to the tumor necrosis factor
(TNF) and the Fas ligand/receptor interactions play an important role in the regulation of
the immune system and the progression of cancer.
1.3.3 Inactivation of immune cells
In the presence of tumour cells, there may occur several interactions between the immune
cells (NK and CD8+ T-cells) the result of which is a failure by these cells to effectively
destroy more foreign cells that may be present in the body. In addition, the NK cells can
cause the inactivation of CD8+ T-cells which occurs mainly when there are high levels of
CD8+ T-cells without responsiveness to the cytokines (Gett et al., 2003). While the exact
cause of these is scientifically unknown, there is evidence from experimental data that in
the absence of the NK cells, the CD8+ T-cells proliferate at a higher rate. Rosenberg and
Lotze (1986) noted that the inactivation of immune cells happens even when there are
tumour cells in the body.
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1.4 Mathematical background of tumour modeling
The first mathematical models of tumour growth were formulated and analysed with the
aim of reproducing and providing mathematical explanations to experimentally observed
tumour growth curves (Billy et al., 2013). According to surveys done by Friberg and
Mattson (1997) and Rodriguez-Brenes et al. (2013), the most common laws that have
been used in tumour modelling over the past decades include: power law, power law with
linear death, Gompertz model, generalized logistic model, logistic model (when β = 1 in
the generalized logistic model) and exponential model (when β = ∞ in the generalized
logistic model). Table 1.1 presents the equations and the respective solutions of each of the
mentioned models. For comparison purposes of the exponential, Gompertz and logistic
models, see Figure 1.3.





α N = (N0 + (1 − α)rt)1−α
when α < 1
Gompertz model
dN


































K +N0 (ert − 1)
Exponential growth
dN
dt = rN N(t) = N0e
rt
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Figure 1.3: Comparison graphs for the Exponential, Logistic and Gompertz models for
tumour growth.
1.5 Cancer treatment by chemotherapy
Treatment of cancer by chemotherapy involves the administration of one or more drugs
with the aim of killing tumour cells, that exhibit rapid and uncontrollable division and
growth. Most chemotherapy drugs that are administered to cancer patients specifically
target cells that are actively dividing (Chabner and Longo, 2011). Chemotherapy drugs
causes the cell to die either by attaching to the cell during the S phase eventually interfering
with its DNA replication, or during the M phase, in which case it disrupts the actual
division of the cell.
Once delivered to the blood stream, chemotherapy drugs begin to decay at a rate which
some researchers have modelled using the term F (M) = 1− e−M . Rosenberg and Lotze






where φi are the different cell populations included in the model of equations. This thesis
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will adopt the above function to describe the loss of cell populations T (t), N(t), L(t), C(t)
and R(t) by subtracting it from the mentioned cell populations.
1.5.1 Pharmacodynamics - Efficacy
Anti-cancer drugs target tumour cells, which are characterized by uncontrolled division
and growth. As noted earlier, these drugs kill cells in certain phases of their cell cycle
which therefore means that only a fraction of them can be killed. This fractional kill rate




At some point, the fractional kill rate reaches a saturation level and no more tumour cells
can be killed by the drug. Further, Peters and Dansey (1997) in their work showed that
the growth of tumours with targeted chemotherapy treatment can be modeled using the









where N(t) denotes the number of tumour cells at any time t. K and λ are the growth pa-
rameters of the Gompertz growth equation and λN(t) defines the total number of tumour
cell that are lost which depends on the concentration of the drug. This term as appears in
equation (1.3) has been simplified to keep both the equation and discussion simple.
1.5.2 Pharmacodynamics - Toxicity
When cancer drugs are introduced into the body, not only do they kill the tumour cells but
also normal body cells. This consequently leads to chemotherapy related side effects that
include:
• A reduction in the production of leukocytes, erythrocytes and thrombocytes.
• Pain and inflammation of the body’s mucous membrane.
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• Hair loss that is the result of hair follicle cells begin attacked by the drugs.
In general, the release of bone marrow cells to proliferation, maturation and to the blood is
severely disturbed by chemotherapy leading to a fall in the cell levels of the patient. There
is therefore a need to ensure that the fall in the cell count as a result of chemotherapy
administration does not become extensively large for cancer patients.
1.6 Problem statement
Despite the impressive amount of research work that has been carried out in cancer, there
has not been a universally accepted effective model that provides the optimum drug con-
centration level which maximizes efficacy while at the same time keeping the toxicity
levels as low as is possible. By combining knowledge from different fields, precisely,
mathematics, computation and medicine, this research has formulated and analyzed a
mathematical model for tumour growth with the aim of addressing the above limitation.
1.7 Research objectives
This research investigated one main objective and two specific objectives which are as
outlined below:
Main objective
To mathematically determine the level of chemotherapeutic drug concentration admin-
istered which maximizes efficacy on malignant tumour cells while keeping the toxicity
levels to normal body cells as minimal as is possible.
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Specific objectives
1. Formulate and analyze a mathematical model describing the interaction of tumour
cells, normal body cells under targeted chemotherapy treatment.
2. Determine the impact of chemotherapy treatment on both tumour and normal body
cell population over time.
1.8 Summary of chapters
The remainder of this thesis consists of three chapters. In chapter 2, a review of relevant
literature is presented with particular focus on the tumour growth models that set the foun-
dation for the formulation of the model developed in this research as well as the original
models that were modified to come up with the new mathematical model.
In chapter 3, a mathematical model for the interaction between tumour cells, immune cells
(NK and CD8+ T-cells) and chemotherapy is presented. In this description, a series of six
coupled ordinary differential equations is formulated and three cases considered namely:
no tomour and no treatment, tumour with no drug and finally, tumour with treatment. The
stability of each of these cases is analyzed with the aim of determining the oscillatory
behaviour of the system.
Chapter 4 summaries the results of the research as presented in Chapter 3. The chapter also
includes conclusions and recommendations that could be undertaken in future research to





Mathematical modelling to study and explain the dynamics of tumour growth, their in-
teraction with immune cells, other body cells, drugs among others has been an area of
great interest and exploitation by a majority of mathematical modelling scientists since
the mid 60s (Mallet and De Pillis, 2006). The earliest models were developed by Burton
(1966) and Greenspan (1972) at which time, their models only focused on simple chemical
diffusion and differential equations.
Currently however, modelling of tumours and their interactions has been expanded to
incorporate the use of advanced mathematical techniques that include ordinary differen-
tial equations (Enderling and Chaplain, 2014), partial differential equations (Hillen et al.,
2015), stochastic differential equations (Lisei and Julitz, 2008) and cellular automata
(Poleszczuk and Enderling, 2014). In addition, developed models are being tested and
validated using in vitro tumour growth data (Li et al., 2010) which is indisputably an
important aspect of modelling as it verifies that developed models predict the real phe-
nomena, and that the treatments proposed are biologically significant.
2.2 Early tumour growth models
There have been several explanations for the underlying mechanism in tumour growth
retardation as exhibited in exponential growth models. While Laird (1964) argues that
according to the available data, the retardation is due at least in part to an actual increase
in the mean generation time during tumour growth, Mayneord (1932) in his earlier work
had showed that such a retardation is as a result of the formation of a necrotic region in
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the centre of a tumour, which has the effect of gradually reducing the region of active
tumour cell growth to a thin shell at the tuomour surface. The findings by Mayneord
were considered favourable by Burton (1966) who formulated a model that examined both
the distribution of oxygen in spherical tumours and relative radius of the central zone to
the total radius. In this model, Burton studied the effect of diminishing growth fraction
while keeping the rate of mitotic activities constant. In this way, he was able to overcome
the limitation of the Gompertzian relation by showing that the growth of tumours can be
explained by a linear model, a fact that has overtime been proved to be true experimentally.
Greenspan developed a mathematical model of tumour growth by diffusion with the aim
of investigating the evolution of solid carcinoma Greenspan (1972). Greenspan’s work
was an extension of the model developed by Burton (1966) and that of Thomlinson and
Gray (1955) which he achieved by introducing a surface tension among the living tumour
cells in order to maintain a compact, solid mass and by assuming that necrotic cellular
debris continually disintegrate into simpler chemical compounds that are freely permeable
through cell membranes. He thus was able to explain the existence of a steady-state tumour
size by showing that the inward motion of cells from the outer region due to adhesion and
surface tension replace the tissues that are lost due to necrosis. In this paper, Greenspan
describes, the shape of a growing tumour as a sphere with three layers namely: a central
necrotic core, quiescent layer of non-proliferating cells and the proliferating zone where
all mitosis occur. These three layers are illustrated in Figure 2.1
Figure 2.1: Layers of a growing tumour
In this paper also, Greenspan made the assumption that a chemical is produced some-
where within the tumour volume which has an inhibiting effect on the mitosis of cancer
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cells without necessarily resulting into their death. To study these effects, he developed
a model by applying the conservation of mass principle, which after a series of mathe-
matical derivations led to an integro-differential equation given in Equation (2.1), which







S(α, β) r2 dr − λR3i (2.1)
whereR0(t) is the radius of tumour at any time t,Ri(t) is the radius of necrotic core,Rg(t)
is the radius at which cell proliferation ceases, S(α, β) is the proliferation rate of cells, α,
β and λ represent concentration of nutrients, concentration of inhibitors and proliferation
constant at which the necrotic core loses cell volume respectively. From this model, he
concluded that the development of tumour spheroids was characterized by three distinct
phases namely: an initial exponential phase, followed by some degree of retardation in
growth which then culminated into a final phase of dormancy as a result of both mitotic
inhibition and tumour cell death. It was however shown from the model that there were
different growth patterns prior to arriving at a steady state, an outcome that Greenspan
himself was not able to explain but proposed it for future experiments. Unfortunately, no
such experiment seems to have been successfully undertaken.
Greenspan also extended his earlier work Greenspan (1972) in which he considered the
stability to asymmetric perturbations of the spherical shape of an equilibrium sized tu-
mour (Greenspan, 1976). While doing this work, he paid attention to the experiments
done by Sutherland et al. (1971) in which the authors had found that some cell aggregates
disintegrated at a certain stage of development. In this paper, Greenspan explained the
distribution of nutrients to the growth of cell cultures and solid tumours by investigating
the unstable development of tumours when surface tension and adhesion are overcome
by internal pressure. The model he developed described the relationship between nutrient
concentration, pressure on the surface and surface tension forces. He concluded that if
the tumour reaches a critical size beyond which surface tension is overcome by pressure
forces, then the tumour becomes unstable.
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The work by both Burton (1966), Greenspan (1972) and Greenspan (1976) were based on
the assumption that oxygen consumption per unit volume per unit time by the cells was
constant. However in his paper, Deakin (1975) made the argument that this assumption
contradicted the experimental results as had been presented by Sutherland et al. (1971)
in which they had shown that viable rim thickness decreases relatively slowly following
the onset of necrosis. He therefore extended their models by incorporating an oxygen
consumption that was proportional to the oxygen concentration within critical limits. By
varying the model parameters, Deakin was able to show that the results of the model
agreed with the available experimental evidence.
Whereas the model by Deakin was restricted to the effect of non-uniformity of the amounts
of oxygen consumed on the viable rim thickness, the model developed by McElwain and
Ponzo (1977) investigated the effect of this non-uniformity on the rate of growth of a
tumour. This model, just as was the case with Greenspan (1972), exhibited three phases
that were distinct. In the first phase, the model showed that oxygen concentration was
above the critical value everywhere, resulting in a uniform consumption of oxygen by all
cells which consequently gave raise to an exponential growth of the tumour. This was
followed by a decreased growth rate in the second phase due to a reduction of oxygen in
the central region which caused a decrease in the effective proliferation rate. The final
stage was characterized by viable dormancy with reduced proliferation. Evidently, this
model results are significantly different from those found by Greenspan (1972) discussed
earlier.
The above early models were discussed for they provided a clear understanding into the
growth of tumour cells and further formed a framework for the ODE-based model that was
developed and analysed as part of this research.
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2.3 Tumour, immune system and drug interaction models
A good understanding of the interaction between drug, immune system and tumour cells is
critical to the formulation of ODE based models in this study. The study of the interaction
between tumour, immune system and drug has attracted an abundance of mathematical
models over the past few decades. de Pillis et al. (2005) presented a mathematical model
describing tumour-immune interactions focusing on the role of natural killer cells (NK)
and CD8+ T cells in tumour surveillance. To construct the model, the authors considered
three cell populations namely: tumour cell population, total level of NK cells effective-
ness and total level of tumour-specific CD8+ T cells effectiveness. They found that the
traditional power law of tumour growth representation did not fit well to the available
experimental results which led them to formulate a new law presented in Equation (2.2)
D = d (L/T )
λ
s+ (L/T )λT (2.2)
where L and T is the tumour-specific CD8+ cell effectiveness and tumour cell population
respectively; d and s is the saturation level of fractional tumour cell kill by CD8+ T cells
and the steepness coefficient of tumour CD8+ T cell competition term respectively. Fur-
ther, they established a clear distinction between the NK and CD8+ T cells dynamics in
tumour surveillance. In an earlier paper de Pillis and Radunskaya (2001), the two popula-
tions NK and CD8+ T cells had both been considered as single population –– the immune
cells. Another notable finding from the numerical analysis was that the activation of CD8+
T cells was important in cancer therapy. In the model formulated in this research, the NK
and CD8+ T cells were considered as separate populations thanks to the findings by this
authors, and that each of them had different interaction and recruitment rates.
de Pillis et al. (2007) while investigating tumour-immune interaction developed a math-
ematical with four four populations including drug therapy. Their model described the
growth, death and interaction of these populations with targeted chemotherapy treatment.
Whereas in their earlier model they had used the population of normal body cells N(t),
in this new model, they decided to consider the circulating lymphocyte population which
they denoted by C(t). In such a setting, they aimed at keeping the normal cells above
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some threshold level required for minimal level of patient health. They extended the anal-
ysis to an optimal control problem whose solution they obtained by using the collocation
method Biegler (2007) over a simulated time period of 150 days. From the results of their
simulations, the authors showed that the traditional therapy fails to bring the system to the
zero-tumour burden state when the immune system of the host is weak. With the applica-
tion of the drug therapy solution however, the authors found that the population of tumour
cells goes to zero but the normal cells population remain above the constraint level.
In their subsequent paper de Pillis et al. (2009), which was an extension of their previ-
ous work de Pillis et al. (2006), the authors noted that the understanding of the immune
system is critical to the understanding of tumour growth and that if immunotherapy and
chemotherapy are to be administered simultaneously in a clinical setting, then their in-
teraction (immuno and chemo) and their interaction with the host cells must be properly
understood. In this model, they formulated a system of six differential equations where
they again used the ratio form for the CD8+ T-cell kill rate of tumour cells given in Equa-
tion (2.2), a law they had formulated in their earlier work de Pillis et al. (2005). They
updated this work by removing the term
gT 2N
h+ T 2 which they thought would be insignifi-
cant in addition to introducing complexity to the model. Further, they included the term
IL− 2 (induced NK cell proliferation) and PNNI
gN + I
in this new model.
From their simulation results with no therapy and for large initial tumour size, the immune
system is not able to destroy the tumour which causes its population to grow to the high tu-
mour equilibrium. Introducing chemotherapy was however found to eliminate the tumour
population rapidly. Similarly, combined therapy (chemo and immuno) destroys the tumour
cells but leads to a slight drop in the population of NK and CD8+ T cells to a level that
was still consistent with the results found by Jurisic et al. (2007). Their model indicated
that if the CD8+ T cell kill tumour cells more effectively than immunotherapy, it may
be more useful to administer immunotherapy and chemotherapy simultaneously. With
the availability of individual data for CD8+ T cell effectiveness in killing tumour cells,
the authors suggested that the feasibility of using immunotherapy in combating growing
tumours could be determined. Regrettably, from the available literature, no research to
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determine this has been undertaken to date. We relied heavily on this work by de Pillis
et al. (2009) to formulate the model presented and analyzed in this research by making a
few modifications and improvements as illustrated in Section 3.1.
2.4 Models developed in this project
This literature review has demonstrated that so far, there has been a significant progress
in tumour growth modelling with particular interest in the interactions that occur within
the host tissue as a result of the presence of tumour cells in the body. Despite all this,
the review suggests that the dynamics of tumour growth and normal body cell count under
targeted chemotherapy treatment has not been fully studied, and as a result, research in this
area is still open. The new model developed as part of this research expanded upon existing
models to provide a more complete picture of the interaction between growing tumours
and the host immune system, especially with regard to individual level cell interactions. In




3 Models for Chemotherapeutic Efficacy and Toxicity
3.1 Introduction
Mathematical models of the interaction between tumour, immune and normal body cells
populations provided an excellent frame work for addressing specific questions about
tumour-immune interaction dynamics in addition to the response of tumour cells to treat-
ment, and in particular, treatment by chemotherapeutic drugs. The new model developed
as part of this research is a modification of the work done by de Pillis et al. (2009) in
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D = d(L/T )
l
s+ (L/T )l
In this model, the authors used T (t), N(t), L(t), C(t), M(t) and I(t) to denote tumour
cells, natural killer cells, CD8+ T cells, circulating lymphocytes, chemo and immuno-
therapeutic drug concentrations respectively.
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In the new model formulated in this research, the following modifications were made to
the model by de Pillis et al. (2009), as presented in equations (3.1).
i.) In the first equation, the decay of tumour cells is denoted by the term −δdLT instead
of −DT where D = d (C/T )
λ
s+ (C/T )λT as used in the de Pillis et al. (2009) model.




q + T in the second
equation because the new model did not investigate the role of immuno-therapy in
the activation of CD8+ T-cells.
iii.) Excluded the terms
θmL





and νL(t) because they are related
to treatment by immuno-therapy.
iv.) Added the red blood cell populations (erythrocytes) to the new model.
v.) The new model did not include the last equation of the original model since its an
equation that describes the dynamics of immuno-therapy drug, something that was
not studied in the new model.
3.2 Model formulation
The mathematical tumour growth model formulated as part of this research considers
five cell populations with their interaction dynamics under treatment by chemotherapeutic
drugs. These cell populations and drug concentration at any time t are given below:
• T (t)− Total population of tumour cells.
• N(t)− Concentration of NK cells per litre of blood (cells/litre).
• L(t)− Concentration of CD8+ T cells per litre of blood (cells/litre).
• C(t)− Concentration of other circulating white blood cells (lymphocytes) not in-
cluding the NK and cells CD8+ T cells per litre of blood (cells/litre).
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• R(t)− Concentration of red blood cells (erythrocytes) per litre of blood (cells/litre).
• M(t)− Concentration of chemotherapy drug per litre of blood (mg/litre).
To formulate the model equations, the following key assumptions were made:
i.) The tumour cell populations, in the absence of immune response and drug therapy is
governed by the logistic growth equation.
ii.) All cell populations are homogeneous (i.e. the cells exhibit similar growth dynamics
for all parts of the population).
iii.) The negative interaction between tumour cells with the body cell populations is ac-
counted for in the respective natural death terms of these populations.
iv.) Tumour and immune cells exhibit a Lokta-Voltera predator-prey type of competition,
in which case the immune cells prey on the tumour cells. Further, it is assumed that
both NK and CD8+ T cells have the capacity to kill tumour cells.
v.) The delivery of chemotherapy drugs at the tumour site is almost immediately after
administration.
Table 3.1 presents the model parameters for the model alongside their respective descrip-
tions.
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Table 3.1: Description of parameters used in the model.
Parameter Description
βt Intrinsic tumour growth rate.
αt Inverse of the carrying capacity of tumour cells.
δt Decay of tumour cells due to attack by NK cells.
δd Decay of tumour cells due to attack by CD8+ T-cells.
νt Chemotherapy induced death rate.
λt Chemotherapeutic efficacy coefficient for tumour cells.
βn Rate of recruitment of NK cells from circulating lymphocytes.
p Rate of tumour induced proliferation in NK cells.
q Saturation level of NK cells.
δn Natural death rate of NK cells.
νn Chemotherapy induced death rate.
λn Chemotherapeutic toxicity coefficient for NK cells.
j Rate of tumour induced proliferation in CD8+ T-cells.
k Saturation level of CD8+ T-cells.
ωl Rate of stimulation of CD8+ T-cells by NK-lysed tumour cell debris.
σl Activation of CD8+ T-cells by other lymphocytes.
δl Natural death rate of lymphocytes.
νl Chemotherapy induced death rate.
λl Chemotherapeutic toxicity coefficient for CD8+ T-cells cells.
βc Rate of production of lymphocytes from the bone marrow.
δc Natural death rate of lymphocytes
νc Chemotherapy induced death rate.
λc Chemotherapeutic toxicity coefficient for lymphocytes.
βr Rate of production of erythrocytes from the bone marrow.
δr Natural death rate of erythrocytes.
νr Chemotherapy induced death rate.
λr Chemotherapeutic toxicity coefficient for erythrocytes.
γ(t) Increase in drug concentration by infusion.
ϕm Rate of elimination of chemotherapy drug from the system.23
3.2.1 Model terms
This section describes the terms included in the formulated mathematical model and the
relevant literature for their source. From here henceforth, the short hand derivative nota-
tion ˙φ(t) will be used in the place of dφ
dt
for convenience purposes (φ = T (t), N(t), L(t),
C(t), R(t) and M(t)).
Drug intervention: ˙M(t)
According to de Pillis and Radunskaya (2001), drug kinetics for chemotherapy treatment
is modelled using an exponential function of the form presented in equation (3.2).
Γ(u) = νφ(1− e−λφM)φ (3.2)
Equation (3.2) represents the fractional cell kill for a particular amount of drug at the site
of tumour where νφ and λφ denote the medicinal kill rate and chemotherapeutic effica-
cy/toxicity for a particular cell population (φ = T, N, L, C and R) in the system. This
equation is subtracted from all the five cell populations to represent the effect of treatment
by chemotherapy both to the tumour cells (efficacy) and normal body cells (toxicity). The
concentration of the chemotherapeutic drug is increased in the system by infusion, a term
that is denoted by γ(t). On the other hand, the drug decays at a rate proportional to ϕ
through metabolic activities such as excretion1 and elimination
Tumour cells dynamics: ˙T (t)
Numerous studies in cancer modelling have shown that in the absence of immune re-
sponse and drug therapy, the growth of tumour cells follows a logistic growth model. This
research, just as was the case with de Pillis et al. (2009), adopts the logistic growth term




1It is understood that excretion as a biological process is also determined by protein and tissue binding
capacity
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recruitment of tumour cells. This population is reduced through its interaction with both
NK and CD8+ T-cells, dynamics that are denoted by (−δtTN ) and (−δdTL) respectively.
Further, the tumour cells decay at a rate proportional to νT as a result of the chemother-
apeutic drug. This decay is accounted for by subtracting the term in equation (3.2) from
this population.
NK cells dynamics: ˙N(t)
According to the paper by de Pillis et al. (2009), it is assumed that in the presence of tu-
mour cells, NK cells are recruited at a rate proportional to βn which depends on the popula-
tions of circulating lymphocytes, hence the term βnC. In addition, the cell-cell interaction
between NK and tumour cells causes NK cells to be recruited to the site of tumour which
is accounted for by the term
pTN
q + T . This expression represents the Michaelis-Menten
term widely used in tumour growth models to govern cell-cell interactions (Kirschner and
Panetta, 1998). The term was chosen in favour of
pT 2N
q + T 2 because the later has been
criticized for possible oversimplification of the steady state assumption without neces-
sary conditions (Lefever et al., 1992). NK cells are reduced by natural death (−δnN )
and chemotherapeutic drug effect with kill rate parameter νn and toxicity coefficient of λt
which lead to the term −νn(1− e−λnM)N .
CD8+ T cells dynamics: ˙L(t)
In the absence of tumour cells, there are no CD8+ T-cells present in the system though
they are present in the bone marrow and lymph nodes (Chabner and Longo, 2011). In the
presence of tumour cells however, these cells are activated as a result of a number of fac-
tors. This research considers three of these factors namely: the interaction between CD8+





, the interaction between NK and tumour cells (−ωlNT ) and
that between lymphocytes and tumour cells (−σlCT ). CD8+ T-cells are, on the other hand
decreased by natural death (−δlL) and toxic chemotherapy effect (−νn(1− e−λnM)N ).
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Other lymphocytes dynamics: ˙C(t)
White blood cells (lymphocytes) are recruited at a constant rate of βc, decrease both as
a result of natural death at a rate proportional to δc and from the effect of chemotherapy
drug with a cell kill rate of νc and toxicity rate of λc These dynamics result in the three
terms namely: βc, −δcC and −νc(1− e−λcM)C respectively.
Erythrocytes dynamics: ˙R(t)
The dynamics of red blood cells are defined by a constant recruitment term of βr, natural
death term denoted by −δrR and chemotherapeutic drug toxicity induced death repre-
sented by −νr(1− e−λrM)C.
The above cell population dynamics are summarized in the compartmental diagram pre-
sented in Figure 3.1. The continuous lines with arrows represent the recruitment (inward
arrows) and decrease (outward arrows) for each of each of the model variables. Dashed
black lines with arrows on the other hand are used to denote the interaction between the
various populations. The dotted lines without arrows indicate that the interaction between
two populations (with no arrows) leads to the signaling/activation of a third population
(CD8+ T-cells in this case). While it deviates from the norm, the use of arrows for dashed
lines has been used to show the direction of effect among the different interacting popula-
tions for purposes of clarity.
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Figure 3.1: A compartmental diagram for the tumour-immune interactions with
chemotherapy treatment. The term δDiφ M(i = 1, 2, 3, 4, 5) for each of the cell cell
population compartments was used to denoted the decrease in the cell populations as
a result of chemotherapy effect denoted in equation (3.3) by: νφ(1 − e−λφM)φ where
(φ = T, N, L, C and R)
3.2.2 Model equations
From the compartmental diagram in Figure 3.1, a series of six coupled ordinary differ-
ential equations representing the five cell populations and chemotherapy drug is given by
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equation (3.3).
˙T (t) = βtT (1− αtT )− (δtN + δdL)T − νt(1− e−λtM)T
˙N(t) = βnC +
pTN
q + T − δnN − νn(1− e
−λnM)N
˙L(t) = jTL
k + T + (ωlN + σlC)T − δlL− νl(1− e
−λlM)L
˙C(t) = βc − δcC − νc(1− e−λcM)C
˙R(t) = βr − δrR− νr(1− e−λrM)R
˙M(t) = γ(t)− ϕmM

(3.3)
In the model, it is assumed that all the parameters (as presented in Table 3.1) together with
their initial conditions are non-negative. That is:
T (0) = T0 ≥ 0, N(0) = N0 > 0, L(0) = L0 ≥ 0, C(0) = C0 > 0 and R(0) = R0 > 0
3.3 Model analysis
The aim of this section is to discover and help understand the mathematical behaviour of
tumour growth, particularly how the presence of the immune cells affects the stability of
a growing tumour both with and without targeted chemotherapy treatment.
3.3.1 Linearization and stability analysis
We first begin by linearizing the system of non-linear equations presented in equation (3.3)
using the Jacobian method. We first present two definitions and one theorem that will be
critical in determining the nature of stability of the equilibrium points for the system of
equations.
Definition 3.1 Equilibria points for a system of equations (also called critical points) are
points X ∈ <2 where
F1(X) = F2(X) = · · · = 0
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If X ∈ <2 is an equilibrium solution, of a system of equations, then the constant function
x1(t) = X1, x2 = X2 define a solution x(t) = (X1, X2) to the system of equations.
Definition 3.2 Let X ∈ <2 be a critical point of a system of ordinary differential equa-
tions of the form x
′ = F (x), then
1. The critical point X is stable if for any ε > 0, there exists δ > 0 such that if a
solution x = φ(t) satisfies ||φ(0)− x|| < δ, then
||φ(t)−X|| < ε
for all t > 0. Here ||X|| =
√
x21 + x22 denotes the Euclidean norm on <2.
2. The critical point X is unstable if it is not stable as defined above.
3. The critical point X is asymptotically stable if there exists a δ > 0 such that if a




Theorem 3.1 (Liapunov’s Theorem). Let f : < → Re be C ′ and x0 ∈ < be a fixed point







matrix and λ1, λ2, · · · , λi is its eigenvalues. Then x0 is;
1. Asymptotically stable if <λi < 0 for all i = 1, 2, · · · , n
2. Unstable if <λi > 0 for some i.
If the eigenvalues all have real parts all equal to zero, then further analysis is necessary.
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3.3.2 Steady states and equilibrium points
No tumour no treatment
In the absence of tumour cells and therefore no treatment, the variables T and M are set
to zero (T = 0,M = 0). Further, the dynamics for tumour cell population and that of the
drug reduce to zero, that is, ˙T (t) = 0 and ˙M(t) = 0. The new system of equations is then
given by equation (3.4).
˙T (t) = 0
˙N(t) = βnC − δnN
˙L(t) = −δlL
˙C(t) = βc − δcC




Next we describe how each of the initial values to be used later were arrived at. The value
of C was found by assuming a lymphocyte count of 3.333 × 109 cells per litre of blood
(Abbas and Lichtman, 2005). NK and CD8+ T-cells count were assumed to form 10%
and 1% of the lymphocytes per litre of blood respectively (Abbas and Lichtman, 2005).
L was taken from de Pillis et al. (2009) whose estimation was based on mathematical
calculations using pharmaceutical information. Lastly, R was estimated from the fact that
erythrocytes form 45% of the blood. Therefore, at the tumour-drug free point, we have the
following initial conditions.
T = 0, N = 3.333× 108, L = 2.526× 104,
C = 3.000× 109, R = 1.350× 1010, M = 0
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The Jacobian matrix of the of the system in equation (3.4) is evaluated as:
−δn 0 βn 0
0 −δl 0 0
0 0 −δc 0
0 0 0 −δr

Since the above matrix is lower triangular, its eigenvalues are the elements on the major
diagonal. That is; (




−δn −δl −δc −δr
)
Using Theorem 3.1, we conclude that the tumour-drug-free equilibrium is stable since all
the eigenvalues are negative. That is, λi < 0 (i = 1, 2, 3, 4, 5).
Large tumour with no treatment
In order to investigate how the cell populations interact, the system of equations is exam-
ined without chemotherapy treatment, that is, the variable M is set to zero (M = 0). The
system in equation (3.5) thus simplifies to
˙T (t) = βtT (1− αtT )− (δtN + δdL)T




k + T + (ωlN + σlC)T − δlL
˙C(t) = βc − δcC




We thus aim to analyze the system to discover how close to the tumour free equilibrium
a patients needs to get to in order to be considered completely cured without the threat of
re-occurrence of the tumour cells. To achieve this we set each of the above equations to
zero and then solve for each of he model variables.
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˙T (t) = 0 ˙N(t) = 0 ˙L(t) = 0 ˙C(t) = 0 ˙R(t) = 0





N∗ = − βnβc (q + T )
δc (Tp− Tδn − qδn)
N∗ = −βc (Tpσl − Tβnωl − Tδnσl − qβnωl − qδnσl)T (k + T )
δc (Tp− Tδn − qδn) (Tj − Tδl − kδl)
T ∗1,2 = 0,−
Lδd +Nδt − βt
αtβt
When equation (3.5) is solved simultaneously, a set of two solutions is returned one of
which is given below (the other solution is a complex analytic expression which we choose
not to include). This solutions indeed agrees with experimental findings that CD8+ T-cells
are absent in the system (L = 0) when there are no tumour cells (T = 0). That is:
C = βc
δc
, L = 0, N = βcβn
δcδn
, R = βr
δr
, T = 0
Evaluating the Jacobian of equation (3.5) results in a Jacobian matrix of order five as is
presented below.
βt (−Tαt + 1)− βtTαt − Lδd −Nδt −δtT −δdT 0 0
pN
q + T −
pTN
(q + T )2
−δn +
Tp
q + T 0 βn 0
jL
k + T −
jTL
(k + T )2
+ Cσl +Nωl ωlT
Tj
k + T − δl σlT 0
0 0 0 −δc 0
0 0 0 0 −δr

Further calculations involving the above matrix result in complex analytic expressions
which we do not present here, instead we turn to the numerical calculations to obtain
the eigenvalues of this matrix. We first calculate the initial conditions for a patient with a
large tumour population who is not on chemotherapy treatment (T = 0,M = 0). Since the
presence of tumour cells causes the immune system to activate CD8+ T-cells, we increase
the value from L = 2.526× 104 to 5.268× 105, a value that was derived by de Pillis et al.
(2009). We use an initial value of T = 4.65928 × 109, which is slightly lower than the
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theoretical value of T = 4.66×109 due to the fact that the response by the immune system
prevents the tumour from attaining its carrying capacity. The values of N,R and C are
left unchanged. These initial conditions are summarized below.
T = 4.65928× 109, N = 3.333× 108, L = 5.268× 105,
C = 3.000× 109, R = 1.350× 1010, M = 0
At this point, we use the above initial conditions together with the parameter values pre-
sented in Table 3.2 to first evaluate the Jacobian matrix numerically. These step results in
the following matrix
−3.665723 −0.001355 −0.001355 0 0
0.00000026 0.054296 0 8.889 0
0.011446 0.135492 0.007396 0.002724 0
0 0 0 −0.0063 0
0 0 0 0 −0.00315

(3.6)
from which we define a characteristic equation presented in equation (3.7) below.
| A− λI | = 0 (3.7)
where A is the matrix in equation (3.6), I is an identity matrix of order equal in magnitude
to the order of A and λ is an arbitrary constant. That is;∣∣∣∣∣∣∣∣∣∣∣∣∣∣∣∣∣∣∣∣∣∣
−3.665722− λ −0.001355 −0.001355 0 0
0.00000026 0.054296− λ 0 8.889 0
0.011446 0.135492 0.007396− λ 0.002724 0
0 0 0 −0.0063− λ 0
0 0 0 0 −0.00315− λ
∣∣∣∣∣∣∣∣∣∣∣∣∣∣∣∣∣∣∣∣∣∣
= 0
Evaluating the above determinant and equating the result to zero results in a 5th order
polynomial in λ which is factored and presented below.
− (1.0λ+ 3.6657) (λ+ 0.0063000) (λ+ 0.0031500) (λ− 0.0073921) (λ− 0.054296) = 0
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When the above polynomial is solved for its roots, five values are obtained which are the















By theorem 3.1, the large tumour equilibrium with no treatment is unstable since
λ1 = 0.007392061304 > 0, λ2 = 0.05429640986 > 0
This result shows that for a large tumour population, the response by immune cells may
not sufficiently eliminate tumour cells. Due to the failure of the immune system to contain
this uncontrollable growth of the tumour, it is expected that its (tumour) population will
continue to grow without bound.
Large tumour with chemotherapy treatment
For the case where a patients has tumour cells and chemotherapy is administered, the
steady states for equation (3.3) is evaluated as follows. The expressions for N∗, L∗ and T ∗
have been left in terms of other variables due to the complexity of the resulting expressions
when further substitution is attempted.
R∗ = − βr
νre−λrM − δr − νr
, C∗ = − βc
νce−λcM − δc − νc
N∗ = βnβc (q + T )(νce−λcM − δc − νc) (e−λnMTνn + e−λnMqνn + pT − Tδn − Tνn − qδn − qνn)
L∗ = − T (CTσl + Ckσl +NTωl +Nkωl)e−λlMTνl + e−λlMkνl + jT − δlT − Tνl − δlk − kνl
T ∗1,2 = 0,−
Lδd +Nδt − νte−λtM − βt + νt
αtβt
For the steady state T ∗1,2, there were two solutions. Since we are dealing with a large
tumour equilibrium, it suffices to assume that T = 0 is not a solutions of the system. Now
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the Jacobian matrix of the model including the chemotherapeutic drug is evaluated to give
the the matrix in equation (3.8).
j11 −δtT −δdT 0 0 −νtλte−λtMT
j21 j22 0 βn 0 −νnλne−λnMN
j22 ωlT j33 σlT 0 −νlλle−λlML
0 0 0 j44 0 −νcλce−λcMC
0 0 0 0 j55 −νrλre−λrMR










q + T −
pTN
(q + T )2
j31 =
jL
k + T −
jTL
(k + T )2
+ Cσl +Nωl
j22 = −δn +
pT


















Using the parameters in Table 3.2 and the initial conditions stated in section 3.3.2, we find
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the following matrix.
−4.69× 10−1 −5.82× 10−9 −5.82× 10−9 0 0
6.86× 10−1 −7.51× 10−2 0 8.89× 100 0
1.32× 10−3 5.82× 10−7 −4.86× 100 1.17× 10−8 0
0 0 0 −4.03× 10−2 0
0 0 0 0 −3.72× 10−2

We again form and solve the characteristic equation given by
| A− λI | = 0 (3.9)
where A is the above matrix. Equation (3.9) is a polynomial of order five whose factors
are given by:
f(λ) = (λ+ 4.8650) (λ+ 0.46902) (λ+ 0.075059) (λ+ 0.040300) (λ+ 0.037150) = 0
The roots of this 5th order polynomial are thus given by the solutions of the function
f(λ) = 0. That is
λ1 = −0.075059, λ2 = −0.46902, λ3 = −4.8650, λ4 = −0.03715 and λ5 = −0.04030
It can be seen that all the λ′is (i = 1, 2, 3, 4, 5) are less than zero. Therefore the large
tumour equilibrium which we found to be unstable when there was no treatment is now
stable. This results therefore show that tumour cells can be eliminated by both the response
of immune cells and the efficacy of the chemotherapeutic drugs.
3.4 Numerical analysis and simulation
To carry the numerical simulation, relevant literatures were reviewed and came up with the
parameters presented in Table 3.2. These parameters were used to numerically evaluate
the results over an interval of 714 days (about two years). Figure 3.2 shows the results of
the numerical simulation plotted on the same figure. In the subsequent pages, these plots
are presented separately for easy of visualization.
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Figure 3.2: Interaction dynamics among tumour, NK, CD8+, other lymphocytes red blood
cells under targeted chemotherapy treatment.
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Figure 3.3: Total population of tumour (cells/litre) against time (in days)
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Figure 3.4: Concentration of Natural killers (cells/litre) against time (in days)
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Figure 3.5: Concentration of CD8+ (cells/litre) against time (in days)
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Figure 3.6: Concentration of other lymphocytes (cells/litre) against time (in days)
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Figure 3.7: Concentration of erythrocytes (cells/litre) against time (in days)
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Figure 3.8: Concentration of chemotherapy drug in mg/l against time (in days)
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Table 3.2: Parameters values used for numerical computations and simulation.
Parameter Value Units Source
βt 4.310× 10−1 Day−1 de Pillis et al. (2009)
αt 1.020× 10−9 Cells−1 de Pillis et al. (2009)
δt 2.908× 10−13 l cells−1 per day−1 de Pillis et al. (2009)
δd 2.908× 10−13 l cells−1 per day−1 Estimated
νt 9.000× 10−1 Day−1 de Pillis et al. (2009)
λt, λn, λl, λc, λr 1.833× 100 l/mg−1 de Pillis et al. (2009)
βn 8.889× 100 - de Pillis et al. (2009)
δn 1.250× 10−2 - de Pillis et al. (2009)
p 6.680× 10−2 Day−1 de Pillis et al. (2009)
q 2.504× 105 Day−1 de Pillis et al. (2009)
νn 6.750× 10−2 Day−1 Catimel (1985)
j 1.245× 10−2 Day−1 de Pillis et al. (2009)
k 2.019× 107 Cells de Pillis et al. (2009)
ωl 2.908× 10−11 Cells−1 per Day−1 de Pillis et al. (2009)
σl 5.847× 10−13 Cells−1 per Day−1 de Pillis et al. (2009)
δl 5.000× 10−3 Day1 Estimated
νl 4.860× 100 Day−1 de Pillis et al. (2009)
βc 1.890× 107 Day−1 de Pillis et al. (2009)
δc 6.300× 10−3 Day−1 de Pillis et al. (2009)
νc 3.400× 10−2 Day−1 Catimel (1985)
βr 1.890× 107 Day−1 Estimated
δr 6.300× 10−3 Day−1 Estimated
νr 3.400× 10−2 Day−1 Estimated




4 Conclusion and Recommendations
We have modified the model developed by de Pillis et al. (2009) and have, by estimating
and/or using available parameter values analysed three equilibrium states namely: no tu-
mour no treatment, tumour with no treatment and tumour with chemotherapy treatment.
The first equilibrium point no tumour no treatment, was found to be stable. The second
equilibrium point, tumour with no treatment was found to be unstable –– the immune sys-
tem on its own is incapable of completely driving the tumour population to zero. At this
equilibrium, the tumour population will as a result continue to grow resulting in a high
tumour burden for the patient. The large tumour equilibrium with treatment was found to
be stable. With the right administration of chemotherapy and a strong immune system for
a cancer patient, the tumour cell population could thus be eliminated completely. It was
also found that presence of chemotherapy drug in the system weakens the immune cells
ability to effectively fight the tumour cells.
From the numerical simulation results, we noted a very sharp drop in the level of white
blood cells with the introduction of the drug in the system. The levels began to rise only
after the drug was completely eliminated from the body, and as depicted from Figure 3.6
it took almost one and a half years for the cells to get back to their initial levels. While
the simulated results did not clearly show a sharp decline in the number of NK and CD8+
T-cells as would have been expected, there was a bit of retardation in their recruitment as
a result of severe toxicity of the drug to born marrow cells where they (NK and CD8+
T-cells) are produced. A lot of precaution should therefore be taken so that the patients
is not bombarded with too much of the chemotherapeutic drug for this is likely going to
weaken the immune cells and therefore drive the system to instability causing the tumour
population to re-grow.
We also edited the model to include red blood cells with the aim of investigating the effect
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of chemotherapy drug to these cells. It was found, as can be seen from Figure 3.7 that the
red blood cell population suffered severely from the toxic levels of the drug. Consequently,
their number dropped significantly with the introduction of the drug, but again began to
rise when the drug was completely eliminated from the body. Unlike the case of the white
blood cells, which got back to their initial cell count, we found that red blood cells are
unable to get back to their original levels even after almost two years. Such a situation
cause patients on chemotherapy treatment to exhibit a much lower red blood count which
ultimately may lead to cases of anemia and further worsen the situation.
Evidently, while chemotherapy drugs are guaranteed to effectively eliminate tumour cells,
the cost of their toxicity to other body cells is quite high and their administration in cancer
management should be taken with a lot of precaution. In future research, we put forth
a number of recommendations that could be done to improve on the model developed
herein, in order to realize better and promising scientific results in the fight against cancer
and chemotherapy related side effects. These recommendations include:
i.) Extending the model to include an optimal control strategy by using objective func-
tions with different combination of constraints. By doing this, it could be possible to
come up with a mathematical model that quantifies the exact chemotherapy drug con-
centration that maximizes efficacy on tumour cells but at the same time minimizing
the levels of toxicity to other normal body cells.
ii.) Including additional cell populations to the model. In particular, it would shade more
light if the model was modified by including additional immune cell populations,
and particularly those that are involved in the signaling and activation of the CD8+
T-cells whenever tumour cells are present in the body, good examples being the CD4
and CD3 cells.
iii.) More equations could be added to the developed model to capture additional details
for example the patients well being –– social, financial and health in order to predict
secure and effective chemotherapy treatment strategies.
iv.) For purposes of justifying the validity of the model and in order to obtain more re-
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cent and relevant model parameters, we recommend that various sets of experiments
be fitted to the model developed in this research. Experimental data from clinical
trials on humans need to be carried out in order to limit the over-reliance on mouse
experiments for model parameters.
v.) The ordinary differential equations could be extended to partial differential equa-
tions. In this case, it will be possible to capture and investigate the spatial character-
istics of tumour cells for example, their ability to metastasize quickly to other parts
of the body.
vi.) The aspect of resistance to drugs by chemotherapy drugs, in addition to combination
therapy could also be investigated in future models.
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Appendix A: Maple codes
Listing 1: Equation (3.3) entered in Maple.
1 ########################################################
2 # Run this file before running syntax in Listing 2 & 3 #
3 ########################################################
4
5 # clear the Maple workspace
6 restart:
7 # Enter the system of differential equations
8
9 # Tumour cells
10 dotT := beta[t]*T*(-T*alpha[t]+1)-delta[t]*N*T-delta[d]*L*T
-nu[t]*(1-eˆ(-lambda[t]*M))*T:
11
12 # Natural killers
13 dotN := delta[n]*(beta[n]*C/delta[n]-N)+m*T*N/(n+T)-nu[n
]*(1-eˆ(-lambda[n]*M))*N:
14
15 # CD8+ T-cells




19 dotC := delta[c]*(beta[c]/delta[c]-C)-nu[c]*(1-eˆ(-lambda[c
]*M))*C:
20
21 # Red blood cells
22 dotR := delta[r]*(beta[r]/delta[r]-R)-nu[r]*(1-eˆ(-lambda[r
]*M))*R:
23
24 # Chemotherapy drug
25 dotM := gamma(t)-varphi[m]*M:
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Listing 2: Model Analysis with no tumour and no treatment (T = 0 & M = 0) for
Equation (3.3).
1 ######################################################
2 # Run the file in Listing 1 before running this file #
3 ######################################################
4
5 T := 0: # No tumour
6 M := 0: # No treatment
7
8 # Steady states
9
10 Rs := solve(dotR,R)
11 Cs := solve(dotC,C)
12 Ns := subs({C = Cs}, solve(dotN,N))
13 Ls := simplify(subs({C = Cs,N = Ns}, solve(dotL,L)))
14 Ts := solve(dotT,T)
15
16 # solve all equations simultaneously and extracting the










25 # Calculate the Jacobian of the system
26
27 JE := Jacobian([dotT,dotN,dotL,dotC,dotR],[T,N,L,C,R])
28 JE0 := subs({T = 0}, JE)
29
30 # form the matrix I_lambda used in the characteristic
equation find eigen values
31
32 I_lambda := lambda*IdentityMatrix(5): # create an identity
matrix of order 5
33 Char_Eqtn := JE0-I_lambda;
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34 det_Char_Eqtn := Determinant(Char_Eqtn) # Eigen values
using the determint
35 eigen_JE0 := Eigenvalues(JE0) # Eigenvalues using the Maple
function
36
37 # Numerical calculations
38
39 JE1 := subs({T = 1,N = 1}, JE)
40
41 JE1C := CharacteristicPolynomial(JE1, lambda):
42 JEE := Eigenvalues(JE1):
Listing 3: Model Analysis with no treatment (M = 0) for Equation (3.3).
1 ######################################################
2 # Run the file in Listing 1 before running this file #
3 ######################################################
4
5 M := 0: # No treatment
6
7 # Steady states
8
9 Rs := solve(dotR,R)
10 Cs := solve(dotC,C)
11 Ns := subs({C = Cs}, solve(dotN,N))
12 Ls := simplify(subs({C = Cs,N = Ns}, solve(dotL,L)))
13 Ts := solve(dotT,T)
14
15 # solve all equations simultaneously and extracting the










24 # Calculate the Jacobian of the system
55
25
26 JE := Jacobian([dotT,dotN,dotL,dotC,dotR],[T,N,L,C,R])
27 JE0 := subs({T = 0}, JE)
28
29 # form the matrix I_lambda used in the characteristic
equation find eigen values
30
31 I_lambda := lambda*IdentityMatrix(5): # create an identity
matrix of order 5
32 Char_Eqtn := JE0-I_lambda;
33 det_Char_Eqtn := Determinant(Char_Eqtn) # Eigen values
using the determint
34 eigen_JE0 := Eigenvalues(JE0) # Eigenvalues using the Maple
function
35
36 # Numerical calculations
37
38 JE1 := subs({T = 1,N = 1}, JE)
39
40 JE1C := CharacteristicPolynomial(JE1, lambda):
41 JEE := Eigenvalues(JE1):
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Listing 4: Model Analysis with treatment for Equation (3.3).
1 ######################################################
2 # Run the file in Listing 1 before running this file #
3 ######################################################
4
5 # Steady states
6
7 Rs := solve(dotR,R)
8 Cs := solve(dotC,C)
9 Ns := subs({C = Cs}, solve(dotN,N))
10 Ls := simplify(subs({C = Cs}, solve(dotL, L))):
11 Ls := subs({lambda[c]+lambda[l] = b, lambda[c]+lambda[l]+
lambda[n] = a}, Ls)
12 Ts := solve(dotT,T)
13
14 # solve all equations simultaneously and extracting the










23 # Calculate the Jacobian of the system
24
25 JE := Jacobian([dotT,dotN,dotL,dotC,dotR],[T,N,L,C,R])
26
27 # form the matrix I_lambda used in the characteristic
equation find eigen values
28
29 I_lambda := lambda*IdentityMatrix(5): # create an identity
matrix of order 5
30 Char_Eqtn := JE0-I_lambda
31 det_Char_Eqtn := Determinant(Char_Eqtn) # Eigen values
using the determint




34 # Numerical calculations
35
36 JE1 := subs({T = 1,N = 1},JE)
37
38 JE1C := CharacteristicPolynomial(JE1,lambda):
39 JEE := Eigenvalues(JE1):
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Appendix B: Matlab codes
Listing 5: Matlab code for Figure 3.1
1 %{
2 THIS SCRIPT SOLVES THE DIFFERENTIAL EQUATIONS ANALYTICALLY
3 AND PLOTS THE RESULTS. NOTE THAT NUMERICAL METHODS COULD
ALSO HAVE BE USED
4 %}
5
6 % define the symbolic expressions (variables & parameters)
7 % r = lambda
8 syms K r N(t)
9 % define parameter values
10 N0 = 0.1;
11 rg = 1;
12 Kg = 1;
13 % Solving the models with initial tumour size of 0.1
14 % Exponential
15 fE = dsolve(diff(N) == r*N,N(0) == N0);
16 fEs = subs(fE,r,rg); % substitute for r
17 % Logistic
18 fL = dsolve(diff(N) == r*N*(1-N/K),N(0) == N0);
19 fL = simplify(fL);
20 fL1 = subs(fL,[r,K],[rg,Kg]); % substitute for r and k
21 fLp = simplify(fL1);
22 % Gompertz
23 fG = dsolve(diff(N) == r*N*log(K/N),N(0) == N0);
24 fG = simplify(fG);
25 fG1 = subs(fL,[r,K],[rg-0.1,Kg]); % substitute for r and k.
26 % Note that r was reduced by 0.1 to avoid overlap of
27 % logistic and Gompertz graphs
28 fGp = simplify(fG1);
29
30 % Plotting the results
31 close all
32 limits = [0 10];
33 ezplot(fEs,limits) % exponential model
34 hold on
35 ezplot(fLp,limits) % logistic model
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36 hold on
37 ezplot(fGp,limits) % Gompertz model
38
39 % graph options
40
41 E = '$$ \frac{dN}{dt} = r\,N $$';
42 L = '$$ \frac{dN}{dt} = r\,N\left(1-\frac{N}{K}\right) $$';
43 G = '$$ \frac{dN}{dt} = r\,N\,ln\left(\frac{N}{K}\right) $$
';
44
45 title('Exponential, Logistic and Gompertz models')
46 xlabel('time (t)')






Listing 6: Function file for Equation 3.3 with parameter values
1 %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
2 % ODE system in Equation 3.3 %
3 %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
4 function dy = modelequations(t,y)
5
6 dy = zeros(6,1);
7
8 % Tumour parameters
9 beta_t = 4.31e0; alpha_t = 1.020e-9;
10 delta_t = 2.908e-13; delta_d = 2.908e-13;
11 nu_t = 9e-1; lambda_t = 1.833e0;
12
13 % NK cells parameters
14 beta_n = 8.889e0; delta_n = 1.250e-2;
15 p = 6.680e-2; q = 2.504e5;
16 nu_n = 6.750e-2; lambda_n = 1.833e0;
17
18 % CD8+ cells parameters
19 j = 1.245e-2; k = 2.019e7;
20 omega_l = 2.908e-11; sigma_l = 5.847e-13;
21 delta_l = 5e-3; nu_l = 4.860e0;
22 lambda_l = 1.833e0;
23
24 % Lymphocytes paramters
25 beta_c = 1.890e7; delta_c = 6.3e-3;
26 nu_c = 3.4e-2; lambda_c = 1.833e0;
27
28 % Erythrocytes parametrs
29 beta_r = 0.75*1.890e7; delta_r = 0.75*6.3e-3;
30 nu_r = 0.75*3.4e-2; lambda_r = 0.75*1.833e0;
31
32 % Chemotherapy parameter
33 varphi_m = 5.199e-2;
34 gammat = 0;
35
36 T = y(1); % Tumour cell populations
37 N = y(2); % Natural kill cells
38 L = y(3); % CD8+ T cells
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39 C = y(4); % Other circulating lymphocytes
40 R = y(5); % Red blood cells
41 M = y(6); % Chemotherapy drug
42
43 % System of equations
44
45 % Tumour: dT/dt
46 dy(1) = beta_t*T*(-T*alpha_t+1)-delta_t*N*T-delta_d*L*T-
nu_t*(1-exp(-lambda_t*M))*T;
47
48 % Natural killer: dN/dt
49 dy(2) = beta_n*C+p*T*N/(q+T)-delta_n*N-nu_n*(1-exp(-
lambda_n*M))*N;
50
51 % CD8+ T: dL/dt
52 dy(3) = j*T*L/(k+T)+(C*sigma_l+N*omega_l)*T-delta_l*L-nu_l
*(1-exp(-lambda_l*M))*L;
53
54 % Other Lymphocytes: dC/dt
55 dy(4) = beta_c-delta_c*C-nu_c*(1-exp(-lambda_c*M))*C;
56
57 % Erythrocytes: dR/dt
58 dy(5) = beta_r-delta_r*R-nu_r*(1-exp(-lambda_r*M))*R;
59
60 % Chemotherapy drugs: dM/dt




Listing 7: M-Script to run the function in Listing 6
1 %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%




6 start_time = 0;
7 interval = 7*3;
8 end_time = interval*17*2;
9 time = start_time:interval:end_time;
10 length(time);
11 Ti = 4.65928e9; Ni = 3.33333e8; Li = 5.268e5;
12 Ci = 3e9; Ri = 4.25e9; Mi = 2.5;
13 initialconditions = [Ti;Ni;Li;Ci;Ri;Mi];
14 [t,y] = ode45(@modelequations,time,initialconditions);
15 % Organize results in a matrix and display on the screen














22 % Create list with the cell populations
23 varslabel = {'1. Tumour cells','2. Natural killer cells','
3. CD8+ T-cells','4. Other Lymphocytes','5. Erythrocytes
','6. Drug concentration'};
24 vars = size(y,2);
25 % Create figures for T(t), N(t), L(t), C(t), R(t) and M(t)
26 close all






32 if (i < 6)





38 % combine into one figure
39 figure(i+1)





45 if (i < 6)
46 ylabel('Conc. (cells per litre)')
47 else
48 ylabel('Conc. (mg/l)')
49 end
50 end
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